Absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV ‐infected, evaluated patients

查看全文 作　　者：A.;H.;Talal;J.;LaFleur;R.;Hoop;P.;Pandya;P.;Martin;I.;Jacobson;J.;Han;E.;J.;Korner 出　　处：《Aliment Pharmacol Ther》索引2013年第4期,共0页